vTv Therapeutics (VTVT) Insider Spiegelman Buys $210K of Stock

Daniel Spiegelman Buys VTVT Shares

Insider transactions at vTv Therapeutics Inc. (NasdaqCM: VTVT) caught attention on June 26, 2026, when Daniel Spiegelman purchased 6,000 shares of the clinical-stage biotech firm. The transaction was executed at $35.08 per share, bringing the total cost of the acquisition to $210,480. This move followed a series of similar open-market buys by other company insiders on the exact same date.

Coordinated Insider Buying Activity

Spiegelman was not the only person stepping up to buy shares during the June 26 session. Fahed Al-Marzooqi also acquired 6,000 shares at $35.08 apiece for a total spend of $210,480. Anne Phillips picked up an identical block of 6,000 shares at the same price point, resulting in another $210,480 investment. Srinivas Akkaraju joined the group by purchasing 6,000 shares at $35.08 for a matching value of $210,480. These concurrent purchases highlight a unified wave of buying among key figures at the firm.

VTVT Stock Valuation and Market Context

Shares of vTv Therapeutics traded near $36.27, holding ground well above the 50-day moving average of $32.35 and tracking close to the 200-day moving average of $34.54. The biopharmaceutical company has experienced a wide trading band over the past year, registering a 52-week low of $19.50 and a 52-week high of $44.00. With a market capitalization near $123.7 million, the stock continues to attract interest as clinical developments move forward.

Analysts Set New Price Targets

Wall Street firms remain active in evaluating the stock's prospects. On October 14, 2026, BTIG reiterated its Buy rating on VTVT with a price target of $57.00. Earlier on August 6, 2026, HC Wainwright & Co. maintained its Buy rating while adjusting its target to $42.00 from $45.00. Prior to that, BTIG maintained a Buy rating on July 16, 2026, lifting its target from $49.00 to $57.00. Across the broader analyst community, the company holds a consensus mean price target of $54.71 based on seven tracked opinions.

About vTv Therapeutics Inc.

Headquartered in High Point, North Carolina, vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic conditions. Its primary candidate is cadisegliatin, an investigational liver-selective glucokinase activator currently evaluated in Phase III clinical trials for type 1 diabetes. The company operates with a lean team of 26 employees and continues to advance its pipeline through various research partnerships.

Outlook and What to Watch Next

Investors monitoring vTv Therapeutics will look toward the upcoming financial results slated for release on November 13, 2026. While insider purchases offer a window into how leadership views the company's valuation, these transactions represent individual decisions rather than corporate guarantees. Market participants will keep watching upcoming clinical trial updates and filing disclosures for further clues on corporate momentum.